U.S. Markets open in 2 hrs 57 mins

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
182.10+5.51 (+3.12%)
At close: 4:00PM EDT

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200
http://www.alnylam.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees1,453

Key Executives

NameTitlePayExercisedYear Born
Dr. John M. MaraganoreCEO & Exec. Director2.07M17.34M1963
Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBAPres & COO1.24M10.1M1963
Mr. Jeffrey V. Poulton M.B.A.CFO & Exec. VP893.47kN/A1968
Ms. Laurie Bartlett Keating J.D.Exec. VP, Chief Legal Officer & Sec.835.16k6.77M1954
Dr. Akshay K. VaishnawPres of R&D1.09M4.23M1963
Dr. Alfred W. Boyle Ph.D.Chief Technical Operations & Quality OfficerN/AN/AN/A
Dr. Kevin FitzgeraldSr. VP & Chief Scientific OfficerN/AN/AN/A
Ms. Christine Regan LindenboomSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Agnieszka Gallagher J.D.Chief Ethics & Compliance OfficerN/AN/AN/A
Mr. Mark BaglinVP of Global MarketingN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG to develop, manufacture, and commercialize RNAi therapeutics for the treatment of proprotein convertase subtilisin/kexin type 9, hypercholesterolemia, and other human diseases; with Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics to treat SARS-CoV-2, the virus that causes the disease COVID-19; Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; and with Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Alnylam Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.